Breaking News Instant updates and real-time market news.

FATE

Fate Therapeutics

$3.09

0.11 (3.69%)

, EXTR

Extreme Networks

$9.32

0.69 (8.00%)

17:41
08/14/17
08/14
17:41
08/14/17
17:41

On The Fly: After Hours Movers

UP AFTER EARNINGS: Fate Therapeutics (FATE), up 16.2%... Extreme Networks (EXTR), up 10.1%... Westport Fuel Systems (WPRT), up 7.3%. ALSO HIGHER: Synchrony Financial (SYF), up 4.6% after Berkshire Hathaway (BRK.A) took a new stake in the company... Pandora (P), up 4.2% after it named Roger Lynch as its new chief executive officer. DOWN AFTER EARNINGS: Photronics (PLAB), down 16.2%... Hollysys (HOLI), down 7.9%... Reata Pharmaceuticals (RETA), down 1.6%. ALSO LOWER: Omeros (OMER), down 5.9% after it filed to sell 3M shares of common stock... Genpact (G), down 2% after it filed to sell 10M shares of common stock for holders.

FATE

Fate Therapeutics

$3.09

0.11 (3.69%)

EXTR

Extreme Networks

$9.32

0.69 (8.00%)

WPRT

Westport

$1.91

0.08 (4.37%)

SYF

Synchrony

$29.64

0.44 (1.51%)

BRK.A

Berkshire Hathaway

$266,369.99

3369.99 (1.28%)

BRK.B

Berkshire Hathaway

$177.29

1.95 (1.11%)

P

Pandora

$8.07

-0.01 (-0.12%)

PLAB

Photronics

$9.85

0.35 (3.68%)

HOLI

Hollysys

$19.01

0.12 (0.64%)

RETA

Reata Pharmaceuticals

$27.44

-0.42 (-1.51%)

OMER

Omeros

$24.61

1.16 (4.95%)

G

Genpact

$29.43

0.11 (0.38%)

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 15

    Aug

  • 15

    Aug

  • 15

    Aug

  • 16

    Aug

  • 23

    Aug

  • 24

    Aug

  • 29

    Aug

  • 05

    Sep

  • 26

    Sep

  • 15

    Aug

  • 15

    Aug

FATE Fate Therapeutics
$3.09

0.11 (3.69%)

09/22/16
ROTH
09/22/16
INITIATION
Target $8
ROTH
Buy
Fate Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Mark Breidenbach started Fate Therapeutics with a Buy rating and $8 price target.
EXTR Extreme Networks
$9.32

0.69 (8.00%)

09/15/16
DADA
09/15/16
UPGRADE
DADA
Buy
Extreme Networks upgraded to Buy from Neutral at DA Davidson
06/09/17
DADA
06/09/17
NO CHANGE
DADA
Extreme Networks price target raised to $14 from $10 at DA Davidson
After meeting with Extreme's management, DA Davidson analyst Mark Kelleher says that the company is poised to close on its acquisition of Avaya networking assets at the end of June. The company's acquisition of networking assets from Brocade could close at the beginning of August, the analyst adds. He says that the company will focus its R&D efforts on one of ihe four operating systems it will have while spending modest amounts on R&D on the other three. Kelleher says that the company's deals may enable it to become " a strong, profitable competitor in the networking market, "and he thinks its revenue can reach $1B when all of its deals are closed. He raised his price target on the shares to $14 from $10 and keeps a Buy rating.
06/05/17
CHLM
06/05/17
NO CHANGE
Target $12.5
CHLM
Buy
Extreme Networks set to enter top 3 in enterprise networking, says Craig-Hallum
Craig-Hallum analyst Christian Schwab noted that Extreme Networks (EXTR) is poised to become the third largest enterprise networking vendor - behind Cisco (CSCO) and HP Enterprise (HPE) - post the closing of its deals with Avaya and Brocade (BRCD). Management has introduced a FY18 target for revenue of over $1B and, combined with its just revealed margin targets, Extreme should be earning 90c-95c per share annually, estimated Schwab, who reiterates his Buy rating and $12.50 price target on the stock following the company's analyst day.
09/15/16
DADA
09/15/16
UPGRADE
DADA
Buy
Extreme Networks upgraded on acquisition at DA Davidson
As noted earlier, DA Davidson analyst Mark Kelleher upgraded Extreme Networks to Buy from Neutral. The analyst says that the deal will expand the company's total addressable market and cross-selling opportunities, enabling it to generate growth again over the next several quarters. Target $5.
WPRT Westport
$1.91

0.08 (4.37%)

SYF Synchrony
$29.64

0.44 (1.51%)

05/26/17
SPHN
05/26/17
NO CHANGE
Target $38
SPHN
Overweight
Stephens suggests pair trade of long Aaron's, short Synchrony
Stephens analyst Vincent Caintic noted that Aaron's (AAN) won of the subprime portion of Signet Jewelers' (SIG) outsourcing of its credit portfolio, with Alliance Data (ADS) winning the prime portfolio, and he thinks there may be more upside to Aaron's revenues from this deal than Signet's financials suggest. Based on his belief that subprime consumer lenders are outperforming prime lenders, he suggests a pair trade of Aaron's long against Synchrony (SYF). Caintic has an Overweight rating and $38 price target on Aaron's shares.
05/03/17
GUGG
05/03/17
DOWNGRADE
GUGG
Neutral
Synchrony downgraded to Neutral from Buy at Guggenheim
05/19/17
WELS
05/19/17
NO CHANGE
WELS
Wells downgrades Credit Card sector on credit concerns
Wells Fargo analyst Jason Harbes downgraded his rating on the Credit Card space to Market Weight from Overweight after attending Card Forum 2017 in Austin, Texas. The analyst keeps Overweight ratings on Synchrony (SYF) and Discover (DFS) and Market Perform ratings on American Express (AXP) and Capital One (COF). Credit trends have recently deteriorated primarily due to weaker underwriting, Harbes tells investors in a research note. The analyst is also concerned about slowing receivables growth following an extended period of acceleration from 2012-2016. He lowered his price target for Synchrony to $30 from $35, for Discover to $70 from $80 and for Capital One to $85 from $88. The analyst keeps an $80 target on American Express.
05/19/17
WELS
05/19/17
NO CHANGE
WELS
Credit card sector lowered to Market Weight from Overweight at Wells Fargo
Wells Fargo cut its rating on the credit card sector to Market Weight from Overweight. The firm noted that the sector's net chargeoffs increased to 3.6% last quarter, representing a four year high. The firm is also worried about slowing receivables growth and increased competition in the space. Despite the downgrade, it continues to recommend Discover (DFS) and Synchrony (SYF). It lowered its price target on Discover to $70 from $80 and cut its price target on Synchrony to $30 from $35. It keeps Market Perform ratings on American Express (AXP) and Capital One (COF).
BRK.A Berkshire Hathaway
$266,369.99

3369.99 (1.28%)

06/27/17
06/27/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Impinj (PI) was downgraded to Sector Weight from Overweight by Pacific Crest analyst Brad Erickson based on valuation. 2. Mizuho analyst Haendel St. Juste downgraded Store Capital (STOR) to Neutral from Buy citing fair valuation following recent strength driven by Berkshire Hathaway's (BRK.A) investment. 3. Camtek (CAMT) was downgraded to Hold from Buy by Needham analyst Y. Edwin Mok, as he expects to see some deceleration as the PCB business normalizes and he believes large orders for back-end semi inspections are already reflected in the stock after its recent run-up. 4. Nomura Instinet analyst Dan Dolev downgraded Cintas (CTAS) to Neutral from Buy after lowering his FY18 uniform rental organic growth forecasts to 5% from 7%. 5. Atlantic Equities analyst Barry MacCarthy downgraded Hess Corp. (HES) and Schlumberger (SLB), both to Neutral from Overweight, given his view of the limited prospects for an oil price rebound. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/16/17
MSCO
05/16/17
NO CHANGE
Target $212
MSCO
Overweight
IBM at attractive entry point ahead of mainframe cycle, says Morgan Stanley
Morgan Stanley analyst Katy Huberty attributes recent weakness in shares of IBM (IBM) to the combination of the news that Warren Buffett's Berkshire Hathaway (BRK.A) cut its stake by a third and the company's weak Q1 gross margin trends. However, growth accelerates and margins expand historically for IBM around a mainframe cycle, making the pullback an attractive entry point, according to Huberty. The analyst, who sees a number of the gross margin pressures that have recently plagued IBM abating in the second half of 2017, has a $212 price target on Big Blue's shares.
03/20/17
03/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Monness Crespi analyst James Cakmak initiated Snap (SNAP) with a Buy and a $25 price target. 2. Workday (WDAY) initiated with a Buy at BofA/Merrill. 3. Berkshire Hathaway (BRK.A) initiated with an Equal Weight at Morgan Stanley. 4. MeetMe (MEET) initiated with a Buy at Canaccord. 5. ARC Document (ARC) resumed with a Buy at B. Riley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/17
LOOP
07/12/17
NO CHANGE
Target $42
LOOP
Buy
Core-Mark unlikely to 'get Amazoned,' says Loop Capital
Loop Capital analyst Andrew Wolf said he sees Core-Mark (CORE) as the least likely company among those he covers to get "Amazoned," or put at risk by Amazon (AMZN) buying a competitor. Its closest competitor McLane, which is owned by Berkshire Hathaway (BRK.B), is highly unlikely to sell to Amazon given that its largest customer is Amazon's rival Wal-Mart (WMT), Wolf tells investors. He keeps a Buy rating on Core-Mark and raised his target on the shares to $42 from $40 citing his increased 2018 EPS forecast.
BRK.B Berkshire Hathaway
$177.29

1.95 (1.11%)

02/22/17
02/22/17
NO CHANGE

Morgan Stanley would not dismiss possibility of Berkshire buying an airline
With Warren Buffett's Berkshire Hathaway (BRK.A) recently disclosing an increase to its overall airline exposure, making the firm a number one or two holder for each of the "Big 4," Morgan Stanley polled investors and found that about 60% do not expect this to be a step towards a full-scale acquisition. However, analyst Rajeev Lalwani said the prospect of Berkshire buying an airline is a possibility that is "not worth dismissing," citing the historical precedent of Buffett's involvement in the rail industry and eventual deal to buy Burlington Northern SantaFe in 2009. The top four U.S. airlines include American Airlines (AAL), Delta Air Lines (DAL), Southwest (LUV) and United Continental (UAL).
01/03/17
ARGS
01/03/17
INITIATION
ARGS
Hold
Berkshire Hathaway initiated with a Hold at Argus
Argus analysts Stephen Biggar and Mike Jaffe started coverage of Berkshire Hathaway with a Hold rating. The analysts expect the company's earnings growth to come in below that of the market in 2017, and they are concerned about the company's succession plan for Chairman and CEO Warren Buffet and Vice Chairman Charlie Munger. The analysts say that the men "will be difficult to replace." They believe that the stock appears to be fairly valued at current levels.
P Pandora
$8.07

-0.01 (-0.12%)

08/01/17
STFL
08/01/17
NO CHANGE
STFL
Pandora price target lowered to $12 from $14 at Stifel
After Pandora reported a lower than expected Q2 per share loss but lowered its revenue guidance, Stifel analyst John Egbert reduced his price target "to reflect a more modest near-term growth outlook." However, the analyst noted that the company expects trends in its ad business to improve in 2H17, and he says that the company's Premium business grew at a "healthy" rate. He keeps a Buy rating on the stock.
08/01/17
ADAM
08/01/17
NO CHANGE
Target $14
ADAM
Buy
Pandora results reinforce company direction, says Canaccord
Canaccord analyst Michael Graham said Pandora's Q2 results reinforced the company's themes of ad revenues, on-demand products, and focus. He notes there are many moving parts to the story but the stock should appeal to a broader base of investors going forward due to increased focus, stronger balance sheet, stronger allies, and a fresh start to expectations. Graham reiterated his Buy rating and lowered his price target to $14 from $15 on Pandora shares.
08/01/17
WEDB
08/01/17
NO CHANGE
WEDB
Pandora to reach profitability faster than previously expected, says Wedbush
After Pandora reported lower than expected revenue but a lower than expected loss, Wedbush analyst Michael Pachter thinks that the company's subscription totals and marketing spending will be lower than he previously expected. As a result;, he expects Pandora to return to profitability more quickly than he previously believed and says that "a return to profitability" this year has become more likely. The analyst keeps a $15 price target and an Outperform rating on the stock.
08/01/17
BOFA
08/01/17
NO CHANGE
Target $7.5
BOFA
Underperform
Pandora price target lowered to $7.50, no turnaround in sight, says BofA/Merrill
BofA/Merrill analyst Nat Schindler said Pandora reported a Q1 beat but guidance was well below the Street. The analyst thinks structural problems are deep and said its hard to see how the model will work without major cost cutting. Schindler said Pandora is challenged by declining users and cut his price target to $7.50 from $9 and reiterated its Underperform rating.
PLAB Photronics
$9.85

0.35 (3.68%)

11/11/16
NEED
11/11/16
DOWNGRADE
NEED
Hold
Photronics downgraded to Hold from Buy at Needham
05/18/17
DADA
05/18/17
NO CHANGE
DADA
Photronics should be bought on weakness, says DA Davidson
After Photronics reported lower than expected EPS, DA Davidson analyst Thomas Diffely expects the company to generate "meaningful growth" going forward, driven by strengthening AMOLED and memory demand. The analyst also expects the company to be helped by its new joint venture in China. He keeps a $15 price target and a Buy rating on the shares.
11/11/16
STFL
11/11/16
DOWNGRADE
STFL
Hold
Photronics downgraded to Hold from Buy at Stifel
Stifel analyst Patrick Ho downgraded Photronics to Hold and lowered its price target to $8.50 from $12 following the negative Q4 preannouncement and said there are no near-term catalysts near-term.
11/11/16
DADA
11/11/16
NO CHANGE
Target $15
DADA
Buy
High end Logic largely responsible for Photronics miss, says DA Davidson
DA Davidson analyst Thomas Diffely notes that Photronics reported preliminary Q4 results below prior expectations, with high end logic largely responsible for the miss. The analyst points out that as Photronics has increased its exposure to the high end mask markets over the past few years it has become better positioned for sustainable long term growth but it has also become more exposed to near term volatility or lumpiness from the relatively large price of high end mask sets. Nonetheless, he believes the company still remains "extremely well-positioned" across multiple key markets to drive significant long-term top-line growth. Diffely reiterates a Buy rating and $15 price target on the shares.
HOLI Hollysys
$19.01

0.12 (0.64%)

02/15/17
DBAB
02/15/17
UPGRADE
Target $20
DBAB
Buy
Hollysys upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Sky Hong upgraded earlier today Hollysys Automation to Buy saying the worst is behind the company following the Q2 results. The analyst sees evidence of an order recovery and has a $20 price target for the shares. Citi this morning downgraded Hollysys to Neutral.
02/15/17
SBSH
02/15/17
DOWNGRADE
Target $18.7
SBSH
Neutral
Hollysys downgraded to Neutral from Buy at Citi
Citi analyst Alex Chang downgraded Hollysys Automation Technologies to Neutral citing the company's "disappointing" Q2 results and lowered outlook. The shortfall in Rail Transportation new orders indicates near-term earnings risk while there could be another round of down-cycle suspension/call-off of power projects in Industrial Automation, the analyst contends. He cut his price target for the shares to $18.70 from $24.40.
01/17/17
DBAB
01/17/17
DOWNGRADE
DBAB
Hold
Hollysys downgraded to Hold from Buy at Deutsche Bank
RETA Reata Pharmaceuticals
$27.44

-0.42 (-1.51%)

07/24/17
PIPR
07/24/17
NO CHANGE
Target $60
PIPR
Overweight
Reata Pharmaceuticals price target raised to $60 from $53 at Piper Jaffray
07/25/17
SBSH
07/25/17
NO CHANGE
Target $87
SBSH
Buy
Reata Pharmaceuticals price target raised to $87 from $39 at Citi
Citi analyst Yigal Nochomovitz more than doubled his price target for shares of Reata Pharmaceuticals to $87 from $39. The clinical-stage biopharmaceutical company closed yesterday up $4.37, or 14%, to $35.47. The company yesterday reported "unexpected and highly impressive" results from a Phase 2 trial testing Bardoxolone in Alport Syndrome, Nochomovitz tells investors in a research note. The data suggest "very meaningful disease reversal," the analyst argues. He believes the planned Phase 3, with data expected in 2019, should work with at least a 60% probability. Nochomovitz keeps a Buy rating on Reata shares.
05/09/17
SBSH
05/09/17
NO CHANGE
Target $39
SBSH
Neutral
Reata Pharmaceuticals price target raised to $39 from $32 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Reata Pharmaceuticals to $39 after re-analyzing the market size for pulmonary arterial hypertension patients in the U.S. The analyst raised his patient population estimate in the U.S. to 27,000 from 11,000 while lowering the peak share potential for Reata's PAH drug to 20% from 30%. Nochomovitz keeps a Buy rating on the shares.
04/13/17
LTCO
04/13/17
INITIATION
Target $55
LTCO
Buy
Reata Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg analyst Matthew Kaplan initiated Reata Pharmaceuticals with a Buy and a $55 price target saying its lead program, bardoxolone methyl, is currently in Phase 3 development for the treatment of connective tissue disease-associated PAH. The analyst expects a strong readout for the CARDINAL study in 1H 2018 based on Phase 2 strength and expects approval in mid-2019. Additionally, REATA has orphan disease opportunities for omaveloxolone in Friedreich's ataxia and mitochondrial myopathy positioning the company to deliver highly differentiated products for attractive markets, the analyst wrote.
OMER Omeros
$24.61

1.16 (4.95%)

05/11/17
CANT
05/11/17
DOWNGRADE
Target $15
CANT
Neutral
Omeros downgraded to Neutral from Overweight at Cantor
Cantor analyst Elemer Piros downgraded Omeros to Neutral and lowered its price target to $15 from $21 following the slightly weaker than expected Q1 report. The analyst has tempered his estimates for the US commercial ramp in peak market penetration to 25% from 30% and views shares as fully valued.
G Genpact
$29.43

0.11 (0.38%)

08/03/17
WEDB
08/03/17
INITIATION
Target $33
WEDB
Neutral
Genpact initiated with a Neutral at Wedbush
Wedbush analyst Moshe Katri initiated Genpact with a Neutral and a $33 price target.
11/29/16
PIPR
11/29/16
NO CHANGE
Target $29
PIPR
Overweight
H-1B visa restrictions would be positive for Genpact, says Piper Jaffray
Piper Jaffray analyst George Tong says he's incrementally more positive on the growth prospects for Genpact following a policy analysis of the Trump administration's stance on immigration reform and H-1B visas. A tightening of H-1B visa quotas will constrain the supply of skilled labor and drive upward pressure on wages, prompting employers to consider business process outsourcing as an alternative to organic hiring, Tong tells investors in a research note. Further, the analyst expects Genpact's competitors in IT outsourcing to be disproportionately harmed by restrictions in the H-1B visa program. Tong has an Overweight rating on Genpact with a $29 price target.

TODAY'S FREE FLY STORIES

FOXA

21st Century Fox

$26.88

0.12 (0.45%)

, ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

20:04
09/24/17
09/24
20:04
09/24/17
20:04
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

FOXA

21st Century Fox

$26.88

0.12 (0.45%)

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

ORCL

Oracle

$48.16

0.19 (0.40%)

GPRO

GoPro

$10.75

-0.19 (-1.74%)

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

SIX

Six Flags

$58.96

1.14 (1.97%)

HMC

Honda

$29.91

0.18 (0.61%)

IRBT

iRobot

$76.14

-3.8 (-4.75%)

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 28

    Sep

  • 12

    Oct

  • 24

    Oct

  • 08

    Nov

  • 12

    Jan

NVCR

Novocure

$21.50

-0.1 (-0.46%)

18:27
09/24/17
09/24
18:27
09/24/17
18:27
Hot Stocks
Combination of Novocure Optune with Temozolomide demonstrates five-year survival »

Novocure announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$102.40

-0.09 (-0.09%)

, CMCSA

Comcast

$38.10

0.63 (1.68%)

17:10
09/24/17
09/24
17:10
09/24/17
17:10
Hot Stocks
Box Office Battle: 'Kingsman: The Golden Circle' easily wins weekend »

"Kingsman: The…

TWX

Time Warner

$102.40

-0.09 (-0.09%)

CMCSA

Comcast

$38.10

0.63 (1.68%)

CMCSK

Comcast

SNE

Sony

$37.50

0.04 (0.11%)

FOX

21st Century Fox

$26.43

0.1 (0.38%)

FOXA

21st Century Fox

$26.88

0.12 (0.45%)

LGF.A

Lionsgate

$31.49

0.24 (0.77%)

DIS

Disney

$98.60

-0.29 (-0.29%)

VIAB

Viacom

$27.64

0.24 (0.88%)

VIA

Viacom

$38.00

-0.2 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 29

    Sep

  • 22

    Oct

  • 26

    Oct

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

16:41
09/24/17
09/24
16:41
09/24/17
16:41
Periodicals
Amazon affiliate to buy stake in Indian retailer Shoppers Stop, Reuters says »

An affiliate of Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

, GOOG

Alphabet

$928.53

-3.92 (-0.42%)

16:37
09/24/17
09/24
16:37
09/24/17
16:37
Periodicals
Internet giants on the defensive in Washington, Reuters says »

Internet giants,…

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

, UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

16:25
09/24/17
09/24
16:25
09/24/17
16:25
Periodicals
Opposition to new 'Obamacare' repeal bill grows, Reuters reports »

The new proposal by…

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

CNC

Centene

$92.22

1.48 (1.63%)

WCG

WellCare

$167.16

1.1 (0.66%)

CI

Cigna

$182.74

0.61 (0.33%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

AET

Aetna

$153.57

0.18 (0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

SAP

SAP

$110.27

0.64 (0.58%)

16:11
09/24/17
09/24
16:11
09/24/17
16:11
Hot Stocks
SAP announces acquisition of Gigya »

SAP has announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TATT

TAT Technologies

$10.70

0.05 (0.47%)

, BA

Boeing

$256.45

0.41 (0.16%)

16:03
09/24/17
09/24
16:03
09/24/17
16:03
Hot Stocks
TAT Technologies awarded APU MRO contract for fleet of Boeing, Airbus »

TAT Technologies (TATT),…

TATT

TAT Technologies

$10.70

0.05 (0.47%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

GM

General Motors

$39.42

0.32 (0.82%)

11:43
09/23/17
09/23
11:43
09/23/17
11:43
Periodicals
GM to eliminate shift at Tennessee SUV plant on 'moderating' sales, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.25

0.19 (0.35%)

11:34
09/23/17
09/23
11:34
09/23/17
11:34
Periodicals
Wells Fargo hires law firm to prepare CEO for Senate appearance, Reuters says »

Wells Fargo has hired law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

EADSY

Airbus

$23.06

-0.01 (-0.04%)

11:27
09/23/17
09/23
11:27
09/23/17
11:27
Periodicals
Airbus in talks to sell all or part of Premium Aerotec, Reuters says »

Airbus is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$102.11

0.56 (0.55%)

11:06
09/23/17
09/23
11:06
09/23/17
11:06
Hot Stocks
Quest Diagnostics 'disappointed' with proposed PAMA 2018 Medicare payment rates »

Quest Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

IRBT

iRobot

$76.14

-3.8 (-4.75%)

10:58
09/23/17
09/23
10:58
09/23/17
10:58
Periodicals
iRobot suffering after onslaught of SharkNinja cheaper models, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.